Clinical Trial Update: Multivalent HPV (Human Papillomavirus) Vaccine Study in 16- to 26-Year Old Men and Women (V503-003) [Phase 3]

View source ↗

Summary

Phase 3 trial update for a multivalent HPV vaccine in 16- to 26-year-olds showing completion and posted results.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Anal Cancer
• Anal Intraepithelial Neoplasia
• Genital Warts

Drugs mentioned

• Merck HPV vaccine (multivalent HPV vaccine) (HPV vaccine)

Snippet

Sponsor: Merck Sharp & Dohme LLC | Conditions: Genital Warts, Anal Cancer | Phase 3 | Status: COMPLETED | Results posted: 2015-03-09